<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168245">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02010099</url>
  </required_header>
  <id_info>
    <org_study_id>PP110 01</org_study_id>
    <nct_id>NCT02010099</nct_id>
  </id_info>
  <brief_title>A Prospective, Randomized, Three Arms, Open Label Study Comparing the Safety and Efficacy of Two Formulations of PP110 to the Active Comparator Preparation-HÂ® Cream in the Treatment of Bleeding Hemorrhoids Grades 2-3</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peritech Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peritech Pharma Ltd.</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eligible patients with bleeding hemorrhoids of grade 2-3 are randomized to test-1 product
      (PP110 Gel), test-2 product (PP-110 medicated wipes) or control (Preparation-H cream).

      Test product usage: once daily, about 1-5 minutes prior to first bowel movement. Control
      product usage: according to label, 3-4 times daily application to rectal region.

      At the end of each day, subject fills a questionnaire regarding bleeding, pain, discharge,
      swelling, itching, discomfort and painkiller usage.

      Treatment is for two weeks, after which subjects  fill a feedback questionnaire addressing
      treatment efficacy and subject satisfaction. Also, at the end of two weeks, subjects are
      examined by study physician who assesses hemorrhoid severity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Bleeding / Spotting</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discharge</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itching</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swelling</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discomfort</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Painkillers usage</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Bleeding Hemorrhoids</condition>
  <arm_group>
    <arm_group_label>PP110 Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PP110 Gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PP110 medicated wipes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PP110 Medicated wipes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preparation-H cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preparation-H cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PP110 Gel</intervention_name>
    <arm_group_label>PP110 Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PP110 Medicated wipes</intervention_name>
    <arm_group_label>PP110 medicated wipes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preparation-H Cream</intervention_name>
    <arm_group_label>Preparation-H cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-70

          2. Bleeding hemorrhoids with / without pain

          3. Diagnosis of internal hemorrhoids of grade 2-3, or external bleeding hemorrhoids

          4. Signed Informed Consent

        Exclusion Criteria:

          1. Known rectal sensitivity

          2. Rectal infection

          3. Grade IV hemorrhoids

          4. Use of anti-coagulants (except Aspirin or Plavix) within 30 days prior to enrollment

          5. Known inflammatory bowel disease

          6. Anal fissure

          7. Military personnel

          8. Female patients that are pregnant, or are not using a reliable method of birth
             control, or are nursing

          9. Patients who have been involved in another experimental trial within the past 30 days

         10. Patients presently diagnosed with cancer
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ehud Klein, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maccabi Healthcare Services, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiryat Ono</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Modiin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramat-Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.peritech-p.com</url>
  </link>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 1, 2014</lastchanged_date>
  <firstreceived_date>December 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Hemorrhoids</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glycerol</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Pramoxine</mesh_term>
    <mesh_term>Petrolatum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
